

#10B  
n.m.  
10/24/021103326-0636**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Lundberg et al.  
Serial No. : 09/646,852  
Filed : September 22, 2000  
For : NEW FORMULATION  
Examiner : DiNola-Baron  
Group Art Unit : 1615

**FAX RECEIVED**

OCT 15 2002

**GROUP 1600****OFFICIAL**

<b>CERTIFICATE OF TRANSMISSION UNDER 37 CFR §1.8</b>	
I hereby certify that this paper is being transmitted by facsimile to the Assistant Commissioner for Patents Washington, D.C. 20231, on October 14, 2002.	
Andrew Fessak Agent Name	48,528 PTO Reg. No.
<i>Andrew Fessak</i> Signature	10/14/02 Date of Signature

**ATTENTION: Examiner Liliana DiNola Baron****GROUP ART UNIT: 1615****NUMBER OF PAGES: 7****FAX NUMBER: 703-305-3592**Assistant Commissioner for Patents  
Washington, D.C. 20231**AMENDMENT**

Sir:

Applicants submit this Amendment in response to the Office Action, mailed July 18, 2002. This communication is being filed within the three-month shortened statutory period for reply and therefore no extension of time should be due.

Serial No. 09/646,852, filed Sept 22, 2000  
Docket No. 1103326-0636  
Page 2 of 7

**Replace claims 1 and 20 with the following amended claims:**

*JMC*  
**1.** (Twice amended) An oral pharmaceutical dosage form comprising a core material coated with a semipermeable membrane, wherein:

*R1*  
the core material comprises an active ingredient selected from the group consisting of omeprazole, an alkaline salt thereof, S-omeprazole and an alkaline salt thereof, one or more alkaline additives, one or more swelling agents, and optionally pharmaceutically acceptable excipients;

the membrane consists essentially of a water-insoluble polymer and a modifying agent and is able to disrupt; and

the dosage form is not enteric coated.

*R2*  
**20.** (Twice amended) A process for the manufacture of a dosage form as defined in claim 1, comprising forming the core material and coating the core material with the semipermeable membrane, wherein the dosage form has no enteric coating.

**Add new claim 27.**

*R3*  
**27.** The dosage form according to any one of claims 11-13, wherein the core material further comprises an osmotic agent.

**REMARKS**

**I. Claim amendments**

Claim 1 has been amended by deleting the "comprising" language from the definition of the semipermeable membrane. As amended, the semipermeable membrane consists essentially